Completed PHASE3 INTERVENTIONAL NCT00074971

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

A Multi-center, Open-Label Extension Study of the Safety and Efficacy of Recombinant Human a-Galactosidase A (r-haGAL) Replacement in Patients With Fabry Disease

Sponsor: Genzyme, a Sanofi Company

Conditions Fabry Disease

Interventions Fabrazyme (agalsidase beta)

Updated 5 times since 2017 Last updated: Dec 2, 2013 Started: Oct 31, 1999 Completion: Dec 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Fabry Disease, this trial is completed. The trial is conducted by Genzyme, a Sanofi Company and has accumulated 5 data snapshots since 1999. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genzyme, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Amsterdam, Netherlands , Baltimore, United States , Billings, United States , Boston, United States , Chicago, United States , Coral Springs, United States , Hickory, United States , Iowa City, United States , London, United Kingdom and 10 more locations